Cipher Pharmaceuticals Inc. to Post Q3 2024 Earnings of $0.25 Per Share, Stifel Canada Forecasts (TSE:CPH)

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Research analysts at Stifel Canada lifted their Q3 2024 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a research note issued on Monday, August 12th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of $0.25 per share for the quarter, up from their previous forecast of $0.18. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $0.74 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ Q4 2024 earnings at $0.22 EPS and FY2024 earnings at $0.90 EPS.

Separately, Stifel Nicolaus raised Cipher Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from C$9.50 to C$16.00 in a report on Tuesday.

Cipher Pharmaceuticals Trading Up 0.1 %

TSE:CPH opened at C$13.86 on Wednesday. The firm has a market cap of C$334.16 million, a P/E ratio of 11.27 and a beta of 1.05. The company has a current ratio of 7.96, a quick ratio of 2.67 and a debt-to-equity ratio of 0.38. The stock’s 50 day simple moving average is C$9.61 and its 200-day simple moving average is C$8.63. Cipher Pharmaceuticals has a 12-month low of C$3.52 and a 12-month high of C$14.55.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.